NEWS HIGHLIGHTS
Published Studies Related to Fluor-Op (Fluorometholone Ophthalmic)
Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema
after cataract surgery. [2011]
DESIGN: Randomized double-masked single-center clinical trial... CONCLUSION: Nepafenac was more effective than fluorometholone in preventing
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2009.08]
PURPOSE: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)... CONCLUSIONS: In patients with SAC, olopatadine, ketotifen, epinastine and emedastine are more efficacious than fluorometholone acetate in preventing itching and redness. All the antiallergic agents gave similar results in terms of reducing tearing, chemosis and eyelid swelling. Our data showed that impression cytology parameters improved after treatment with antiallergic agents in patients with SAC.
Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. [2009.06]
AIMS: Bromfenac sodium (BF) 0.1% was compared with fluorometholone (FML) 0.02% for the treatment of seasonal allergic conjunctivitis when concomitantly used with disodium cromoglycate (DSCG) 2.0%... CONCLUSIONS: Bromfenac sodium for allergic conjunctivitis was effective, with efficacy equivalent to that of FML when used with DSCG.
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2008.07.08]
Purpose: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)... Our data showed that impression cytology parameters improved after treatment with antiallergic agents in patients with SAC.
Comparison of tacrolimus, fluorometholone, and saline in mild-to-moderate contact
lens-induced papillary conjunctivitis. [2012]
contact lens-induced papillary conjunctivitis (CLPC)... CONCLUSIONS: Tacrolimus 0.05% may be a safe and effective treatment for mild to
Clinical Trials Related to Fluor-Op (Fluorometholone Ophthalmic)
An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease [Recruiting]
In this study different mass of the radioligand AZD4694 will be given to patients with
Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the
best opportunities for following disease progress and treatment effects.
Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC) [Recruiting]
Present imaging modalities for primary liver cancer (hepatocellular carcinoma or HCC) have
several shortcomings. One important shortcoming is the time delay between successful
treatment and radiological confirmation of this response. Often it takes several months for
anatomical changes to occur and to be appreciated on morphological imaging such as CT or MRI
(shrinkage of tumor, absence of contrast enhancement). Functional imaging by means of
Fluor-18 deoxyglucose or Fluor-18 Choline (positron emitters, PET-scan) might be an early
indicator of response. This "early" information might help to tailor treatment. For
instance, if no response is induced, an early switch in therapy can be planned.
The present study investigates whether the routine PET-tracer (Fluor-18 deoxyglucose) and
the experimental PET-tracer, Fluor-18 Choline help to predict response if a patient with
inoperable primary liver cancer is treated (radionuclide therapy, biologicals).
Evaluation of [18F]-FMISO for Non Operated Glioblastoma [Recruiting]
Hypoxia is recognized to be an independent predictor of clinical outcome in oncology. PET
using [18F]-FMISO has been described to be useful for the non invasive assessment of hypoxia
in cancer. The use of this radiotracer for brain tumours is very limited and there is no
standard to acquire and quantify [18F]-FMISO uptake. So there is a need for a methodological
evaluation of this PET tracer The purpose of this research is to define optimal parameters
for acquisition and data exploitation to quantify [18F]-FMISO uptake and so predict clinical
outcome in glioblastomas.
Low sensitivity to radiation of glioblastoma is partly caused by hypoxia. Hypoxia in tumours
is not predicted by tumour size. Detecting and monitoring tissue oxygenation are of great
interest to modify therapeutic strategies, including local dose escalation for radiotherapy
or select chemotherapeutic agents with better impact in glioblastomas.
PET with appropriate radiotracers, especially [18F]-FMISO, enables non-invasive assessment
of hypoxia. [18F]-FMISO only accumulates in viable hypoxic cells. So, it has been
demonstrated that PET using 18F-FMISO is suitable to localize and quantify hypoxia. But
there isn't any optimal acquisition protocol or standardized images quantification
treatment. Thus, the interpretation of [18F]-FMISO PET images and the predictive value of
[18F]-FMISO SUV (Standardized Uptake Value) remain unclear explaining the need of
methodological approaches.
Prognostic Evaluation of 18fmiso Pet-ct in Head and Neck Cancer [Recruiting]
Head and neck cancer is the sixth most frequent cancer worldwide, excluding lymphomas and
skin cancer. If 18FDG PET is considered today as a standard tool in patients with head and
neck squamous cell carcinoma (HNSCC) not only for tumoral or nodal staging but also for
assessment of distant metastases and synchronous second primary malignancies, hypoxia is one
of the most important prognostic factors in radiotherapy of this type of tumors. The only
gold standard method for direct determination of oxygen tension is based on using oxygen
electrodes showing a good relation with clinical outcome but complex in its realisation. So,
PET using 18F-FMISO has been described to be useful for the non invasive assessment of
hypoxia in cancer. Especially in France, the use of this radiotracer is very limited and
there is no standardised methodology to acquire and quantify 18F-FMISO signal. So there is a
need for a rigorous evaluation of this PET tracer. In another way, it could be a very useful
tool for evaluation of new therapies and modification of volumes in radiotherapy.
Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer [Active, not recruiting]
To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour
characteristics determined in the plasma of patients with rectal cancer during and after
radiotherapy or combined radiotherapy and chemotherapy.
The changes of the FDG uptake of the primary tumour and the evolution of key tumour
characteristics during radiotherapy alone or in combination with chemotherapy will be
predictive for the pathological tumour response.
Study hypothesis The changes of the FDG uptake of the primary tumour and the evolution of key
tumour characteristics during radiotherapy alone or in combination with chemotherapy will be
predictive for the pathological tumour response.
|
